KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $196.9 million.

  • Sarepta Therapeutics' Income towards Parent Company rose 294857.59% to $196.9 million in Q2 2025 from the same period last year, while for Sep 2025 it was $355.7 million, marking a year-over-year increase of 19227.85%. This contributed to the annual value of $235.0 million for FY2024, which is 14382.98% up from last year.
  • As of Q2 2025, Sarepta Therapeutics' Income towards Parent Company stood at $196.9 million, which was up 294857.59% from $158.8 million recorded in Q4 2024.
  • Sarepta Therapeutics' 5-year Income towards Parent Company high stood at $196.9 million for Q2 2025, and its period low was -$516.8 million during Q1 2023.
  • For the 5-year period, Sarepta Therapeutics' Income towards Parent Company averaged around -$72.2 million, with its median value being -$48.1 million (2021).
  • Per our database at Business Quant, Sarepta Therapeutics' Income towards Parent Company crashed by 85615.14% in 2021 and then skyrocketed by 294857.59% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Income towards Parent Company stood at -$122.0 million in 2021, then grew by 9.94% to -$109.9 million in 2022, then skyrocketed by 141.44% to $45.5 million in 2023, then skyrocketed by 248.8% to $158.8 million in 2024, then rose by 24.02% to $196.9 million in 2025.
  • Its last three reported values are $196.9 million in Q2 2025, $158.8 million for Q4 2024, and $33.6 million during Q3 2024.